JNJ-56021927
CR103653
Phase 1 small_molecule completed
Quick answer
JNJ-56021927 for Prostatic Neoplasms, Castration-Resistant is a Phase 1 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen Cilag International NV
- Indication
- Prostatic Neoplasms, Castration-Resistant
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed